Late June Pulse Check: Conviction, Caution & Catalysts in Biotech

Playback speed

Share post at current time

Share from 0:00

0:00

Paid episode

The full episode is only available to paid subscribers of The Biotech Capital Compass

Late June Pulse Check: Conviction, Caution & Catalysts in Biotech

From Sarepta’s stumble to United’s resilience and Biogen’s slow burn, we break down what institutional investors are really watching—and what retail noise to ignore.

The Biotech Capital Compass

Jun 25, 2025

∙ Paid

In this edition of the Biotech Capital Compass, we cut through the late-June noise with a spotlight on what’s truly driving biotech stock moves.

We kick off with United Therapeutics (The Biotech Capital Compass’s mid-June 2025 edition), where Tyvaso DPI remains dominant, but recent data from Insmed’s TPIP has investors spooked. Despite a 13% drop, United…

Listen to this episode with a 7-day free trial

Subscribe to The Biotech Capital Compass to listen to this post and get 7 days of free access to the full post archives.